Enliven Therapeutics ELVN Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$98.78M+4.7% | -$103.69M-6.7% | -$97.21M+3.0% | -$100.22M-5.7% | -$94.83M-6.5% | ||
| $203K-22.8% | $263K-11.4% | $297K-5.7% | $315K+1.0% | $312K-1.6% | ||
| $34.62M+1.8% | $34.02M+25.8% | $27.05M+8.0% | $25.04M+11.5% | $22.46M+11.3% | ||
| -$65.47M+6.9% | -$70.3M+1.9% | -$71.67M-1.5% | -$70.58M+4.6% | -$73.96M-1.0% | ||
| —— | —— | —— | $181K+311% | $44K0.0% | ||
| -$145.12M+22.1% | -$186.22M— | —— | —— | —— | ||
| $229.05M+4.5% | $219.24M-15.2% | $258.58M-0.4% | $259.7M+502% | $43.13M-67.6% | ||
| —— | —— | —— | —— | -$47.51M-298% | ||
| -$65.6M+6.9% | -$70.46M+1.9% | -$71.82M-1.5% | -$70.76M+4.4% | -$74M-1.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Enliven Therapeutics generate?
- Enliven Therapeutics (ELVN) generated -$65.5M in operating cash flow over the trailing twelve months.
- What is Enliven Therapeutics's free cash flow?
- After $159.0K of capital expenditures, Enliven Therapeutics's free cash flow was -$65.6M over the trailing twelve months, up 11.3% year over year.
- Where does Enliven Therapeutics's cash flow data come from?
- Every line is extracted from Enliven Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.